Intracerebral and intrathecal infusion of the TGF-beta 2-specific antisense phosphorothioate oligonucleotide AP 12009 in rabbits and primates: toxicology and safety.
Here, we provide first evidence that long-term continuous infusion of highly purified antisense phosphorothioate oligodeoxynucleotides (S-ODN) into brain parenchyma is well tolerated and thus highly suitable for in vivo application. AP 12009 is an S-ODN for the therapy of malignant glioma. It is directed against human transforming growth factor-beta (TGF-beta2) mRNA. In the clinical setting, AP 12009 is administered intratumorally by continuous infusion directly into the brain tumor. In view of this clinical application, the focus of our data is on local toxicology studies in rabbits and monkeys to evaluate the safety of AP 12009. AP 12009 was administered either by intrathecal bolus injection into the subarachnoidal space of the lumbar region of both cynomolgus monkeys and rabbits or by continuous intraparenchymatous infusion directly into the brain tissue of rabbits. Intrathecal bolus administration of 0.1 ml of 500 microM AP 12009 showed neither clinical signs of toxicity nor macroscopically visible or histomorphologic changes. After a 7-day intraparenchymatous continuous infusion of 500 microM AP 12009 at 1 microl/h in rabbits, there was no evidence of toxicity except for local mild to moderate lymphocytic leptomeningoencephalitis. Additionally, AP 12009 showed good tolerability in safety pharmacology as well as in acute toxicity studies and 4-week subchronic toxicity studies in mice, rats, and monkeys. This favorable safety profile proves the suitability of AP 12009 for local administration in brain tumor patients from the point of view of toxicology.
Antisense Pharma GmbH, Regensburg, Germany.
Reimar
R
Schlingensiepen
Michael
M
Goldbrunner
Mara N I
MN
Szyrach
Gerhard
G
Stauder
Piotr
P
Jachimczak
Ulrich
U
Bogdahn
Frank
F
Schulmeyer
Peter
P
Hau
Karl-Hermann
KH
Schlingensiepen
D000818:Animals; D001932:Brain Neoplasms / Q000188:drug therapy; D004353:Drug Evaluation, Preclinical; D005910:Glioma / Q000188:drug therapy; D007276:Injections, Intraventricular; D007278:Injections, Spinal; D008252:Macaca fascicularis; D051379:Mice; D016376:Oligonucleotides, Antisense / Q000008:administration & dosage* / Q000235:genetics / Q000627:therapeutic use / Q000633:toxicity*; D011817:Rabbits; D051381:Rats; D017207:Rats, Sprague-Dawley; D013873:Thionucleotides / Q000008:administration & dosage* / Q000633:toxicity*; D016212:Transforming Growth Factor beta / Q000008:administration & dosage* / Q000235:genetics / Q000633:toxicity*; D053781:Transforming Growth Factor beta2
D016376:Oligonucleotides, Antisense; C509041:TGFB2 protein, human; D013873:Thionucleotides; D016212:Transforming Growth Factor beta; D053781:Transforming Growth Factor beta2